Walter Linz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Walter Linz has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Chester Andrzejewski
Transfusion and Apheresis Medicine Services, Department of Pathology Baystate Medical Center, Baystate Health Springfield Massachusetts USA
2 shared publications- Avery A. Thompson
Brigham and Women's Hospital, Trauma Surgery Boston Massachusetts USA
1 shared publication Becky Heister
Our Blood Institute Oklahoma City Oklahoma USA
1 shared publication- Deborah Jebakumar
Pathology (U.N., D.J.), University of Texas Southwestern Medical Center, Dallas, TX
1 shared publication - Ding Wen Wu
Department of Pathology, New York University Grossman School of Medicine, New York, NY 10016, USA
1 shared publication Evan George
Texas A&M Health Science Center Bryan Texas USA
1 shared publication
Latest Publications
- 8 September 2026
- Published by Wiley in Transfusion
- Vol. 66 (11) , 2144-2154
Optimizing blood resource allocation in Oklahoma: A geospatial analysis of available supply and potential networks of distribution
Background: Blood transfusion is essential for surgical, obstetric, oncologic, and trauma care, but availability may be limited in rural settings. We quantified O‐type red blood cell (RBC) availability, access times, and donor distribution across Oklahoma and surrounding areas in 2024. Methods: Using Esri ArcGIS Pro, we evaluated rural hospitals in Oklahoma and adjacent regions supplied by Our Blood Institute (OBI) in 2024. Hospitals were categorized by critical access designation and O‐type RBC inventory, distinguishing low‐stock from resuscitation ready facilities (≤2 and ≥4 units, respectively). Primary outcomes were geographic variation in RBC inventories and drive times to the nearest hospital stocking ≥2 and ≥4 O‐type units. The secondary outcome was donor distribution. Results: Among 106 rural OBI‐supplied hospitals, 16 (15.1%) stocked <2 units O‐type RBCs, and 23% of rural critical access hospitals stocked 30 min from any hospital stocking O‐type RBCs, and 275,341 (4.0%) from one stocking ≥4 units. Of 245,068 donors, 40.87% were O+ and 8.59% were O−, with clustering that left several low‐stock rural areas with limited donor pools. Conclusion: Most rural OBI‐supplied hospitals maintained adequate O‐type RBC inventories, but a clinically significant minority stocked ≤2 units, insufficient for even a single hemorrhaging patient. Geographic variation in inventory and donor distribution means hemorrhage location remains a determinant of transfusion access. These findings support using local inventory and donor data to inform regional blood allocation, and identify translation of geospatial data into distribution and preparedness strategies as a priority for future research.
- 8 September 2026
- Published by Wiley in Transfusion
- Vol. 66 (11) , 2144-2154
Optimizing blood resource allocation in Oklahoma: A geospatial analysis of available supply and potential networks of distribution
Background: Blood transfusion is essential for surgical, obstetric, oncologic, and trauma care, but availability may be limited in rural settings. We quantified O‐type red blood cell (RBC) availability, access times, and donor distribution across Oklahoma and surrounding areas in 2024. Methods: Using Esri ArcGIS Pro, we evaluated rural hospitals in Oklahoma and adjacent regions supplied by Our Blood Institute (OBI) in 2024. Hospitals were categorized by critical access designation and O‐type RBC inventory, distinguishing low‐stock from resuscitation ready facilities (≤2 and ≥4 units, respectively). Primary outcomes were geographic variation in RBC inventories and drive times to the nearest hospital stocking ≥2 and ≥4 O‐type units. The secondary outcome was donor distribution. Results: Among 106 rural OBI‐supplied hospitals, 16 (15.1%) stocked <2 units O‐type RBCs, and 23% of rural critical access hospitals stocked 30 min from any hospital stocking O‐type RBCs, and 275,341 (4.0%) from one stocking ≥4 units. Of 245,068 donors, 40.87% were O+ and 8.59% were O−, with clustering that left several low‐stock rural areas with limited donor pools. Conclusion: Most rural OBI‐supplied hospitals maintained adequate O‐type RBC inventories, but a clinically significant minority stocked ≤2 units, insufficient for even a single hemorrhaging patient. Geographic variation in inventory and donor distribution means hemorrhage location remains a determinant of transfusion access. These findings support using local inventory and donor data to inform regional blood allocation, and identify translation of geospatial data into distribution and preparedness strategies as a priority for future research.
- 27 November 2021
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 37 (1) , 122-126
Apheresis medicine in the era of advanced telehealth technologies: An American Society for Apheresis position paper part II: Principles of apheresis medical practice in a 21st century electronic medical practice environment
- 27 November 2021
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 37 (1) , 122-126
Apheresis medicine in the era of advanced telehealth technologies: An American Society for Apheresis position paper part II: Principles of apheresis medical practice in a 21st century electronic medical practice environment
- 3 February 2021
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 36 (3) , 494-495
Telapheresis: A new paradigm for “saw and evaluated”
- 3 February 2021
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 36 (3) , 494-495
Telapheresis: A new paradigm for “saw and evaluated”
- 17 August 2020
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 35 (5) , 460-468
Apheresis medicine in the era of advanced telehealth technologies: An American Society for Apheresis position paper Part I: Understanding the basic technologies and apheresis medicine practice models
The wide spread availability and use of sophisticated high‐speed telecommunication networks coupled with inexpensive and easily accessible computing capacity have catalyzed the creation of new tools and strategies for healthcare delivery. Such tools and strategies are of value to apheresis medicine (AM) practitioners if they improve delivery of patient care, enhance safety during a therapeutic apheresis (TA) intervention, facilitate care access, advance technical capabilities of apheresis devices, and/or elevate quality performance within TA programs. In the past several years, healthcare delivery systems' adoption of telecommunication technologies has been fostered by organizational financial and quality improvement objectives. More recently, adoption of telehealth technologies has been catalyzed by the COVID‐19 pandemic as these technologies enhance both patient and provider safety in an era of social distancing. These changes will also influence the delivery of TA services which now can be generally viewed in a tripartite model format comprised of traditional hospital‐based fixed site locales, mobile TA operations and lately an evolving telemedicine remote management model now reffered to as telapheresis (TLA). This communication developed by the Public Affairs and Advocacy Committee of the American Society for Apheresis (ASFA) and endorsed by its Board of Directors, reviews and describes various aspects of established and evolving electronic technologies related to TLA and the practice of AM. In subsequent companion publications, additional aspects to TLA will be explored and ASFA's vision of reasonable, regulatory compliant and high‐quality TLA practices will be expounded.
- 17 August 2020
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 35 (5) , 460-468
Apheresis medicine in the era of advanced telehealth technologies: An American Society for Apheresis position paper Part I: Understanding the basic technologies and apheresis medicine practice models
The wide spread availability and use of sophisticated high‐speed telecommunication networks coupled with inexpensive and easily accessible computing capacity have catalyzed the creation of new tools and strategies for healthcare delivery. Such tools and strategies are of value to apheresis medicine (AM) practitioners if they improve delivery of patient care, enhance safety during a therapeutic apheresis (TA) intervention, facilitate care access, advance technical capabilities of apheresis devices, and/or elevate quality performance within TA programs. In the past several years, healthcare delivery systems' adoption of telecommunication technologies has been fostered by organizational financial and quality improvement objectives. More recently, adoption of telehealth technologies has been catalyzed by the COVID‐19 pandemic as these technologies enhance both patient and provider safety in an era of social distancing. These changes will also influence the delivery of TA services which now can be generally viewed in a tripartite model format comprised of traditional hospital‐based fixed site locales, mobile TA operations and lately an evolving telemedicine remote management model now reffered to as telapheresis (TLA). This communication developed by the Public Affairs and Advocacy Committee of the American Society for Apheresis (ASFA) and endorsed by its Board of Directors, reviews and describes various aspects of established and evolving electronic technologies related to TLA and the practice of AM. In subsequent companion publications, additional aspects to TLA will be explored and ASFA's vision of reasonable, regulatory compliant and high‐quality TLA practices will be expounded.
- 28 March 2019
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 32 (2) , 222-226
Risk of cytomegalovirus transmission by blood products after solid organ transplantation
Cytomegalovirus (CMV) infection and CMV disease are significant contributors to increased morbidity, mortality, and cost for immunocompromised solid organ transplant recipients. Although the most significant risk for CMV transmission is the CMV serological status of the transplant donor and recipient, exposure to blood products is another potential risk factor. Before the era of leukocyte reduction, CMV seronegative products were issued to reduce the risk of CMV transmission, thus rendering the products CMV safe. This approach requires maintenance of two inventories of blood products and continuous donor testing. Leukocyte-reduced cellular transfusion products are also considered CMV safe and are essentially universally available. To minimize the risk of CMV infection in transplant recipients, strategies include use of seronegative blood products or prestorage leukocyte reduction. However, no recent randomized prospective controlled trial directly compares the two CMV safety approaches for transplant recipients. Hence, current policy relies on historic trials and more recent observational studies. As a consequence, though generally considered equivalent approaches, preferred practice varies between centers. This review provides guidance to inform an acceptable practice approach.
- 28 March 2019
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 32 (2) , 222-226
Risk of cytomegalovirus transmission by blood products after solid organ transplantation
Cytomegalovirus (CMV) infection and CMV disease are significant contributors to increased morbidity, mortality, and cost for immunocompromised solid organ transplant recipients. Although the most significant risk for CMV transmission is the CMV serological status of the transplant donor and recipient, exposure to blood products is another potential risk factor. Before the era of leukocyte reduction, CMV seronegative products were issued to reduce the risk of CMV transmission, thus rendering the products CMV safe. This approach requires maintenance of two inventories of blood products and continuous donor testing. Leukocyte-reduced cellular transfusion products are also considered CMV safe and are essentially universally available. To minimize the risk of CMV infection in transplant recipients, strategies include use of seronegative blood products or prestorage leukocyte reduction. However, no recent randomized prospective controlled trial directly compares the two CMV safety approaches for transplant recipients. Hence, current policy relies on historic trials and more recent observational studies. As a consequence, though generally considered equivalent approaches, preferred practice varies between centers. This review provides guidance to inform an acceptable practice approach.
- 21 May 2003
- Published by Wiley in Transfusion
- Vol. 43 (6) , 685
Lack of effect of 2 M urea on Jk(a–b–) cells
- 21 May 2003
- Published by Wiley in Transfusion
- Vol. 43 (6) , 685
Lack of effect of 2 M urea on Jk(a–b–) cells